Insys Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $23.9M | $36.0M | $242.3M | $330.8M | $222.1M | $99.3M |
| Operating income | −$127.7M | −$219.0M | $7.3M | $90.5M | $61.0M | $32.6M |
| Net income | −$20.4M | −$6.5M | $7.6M | $58.1M | $36.1M | $40.4M |
| Total assets | $192.5M | $279.1M | $356.1M | $351.3M | $215.1M | $100.6M |
| Total liabilities | $235.6M | $212.9M | $86.5M | $99.0M | $49.5M | $21.1M |
| Equity | −$43.1M | $66.2M | $269.6M | $252.3M | $163.2M | $79.5M |
| EPS (diluted) | $-0.28 | $-0.09 | $0.10 | $0.77 | $0.49 | $0.70 |
| Shares out. | 73.8M | 72.0M | 71.5M | 35.5M | 22.3M | 33.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −534.2%
- Net margin
- −85.2%
- Return on equity
- 47.3%
- Return on assets
- −10.6%
- Return on capital (ROCE)
- −149.1%
- Liabilities / assets
- 122.4%
- Debt / equity
- —
- Book value / share
- $-0.58
- Revenue growth (YoY)
- −33.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -9.68distress
- Accruals / assets
- 18.5%high accruals
- Beneish M-Score
- -2.62normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 6 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 25, 2019
- NT 10-Qmissed a reporting deadline ↗Aug 8, 2019
- NT 10-Qmissed a reporting deadline ↗May 13, 2019
- NT 10-Kmissed a reporting deadline ↗Mar 15, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Housley AndreceOfficer — Chief Financial Officer | Apr 17, 2019 | Grant | 3,992 | $0.00 |
| Long Andrew GOfficer — Chief Executive Officer | Apr 17, 2019 | Grant | 12,475 | $0.00 |
| Bohlen ElizabethDirector | Mar 4, 2019 | Grant | 8,083 | $0.00 |
| Mahboob VaseemDirector | Mar 4, 2019 | Grant | 8,083 | $0.00 |
| Nance Mark EOfficer — Chief Legal Officer & Gen Cnsl | Jan 25, 2019 | Grant | 10,000 | $0.00 |
| Vanhove GeertruiDirector | Apr 2, 2018 | Grant | 6,000 | $0.00 |
| Motahari SaeedOfficer — President & CEO | Mar 5, 2018 | Grant | 16,000 | $0.00 |
| Long Andrew GOfficer — Chief Financial Officer | Mar 5, 2018 | Grant | 10,600 | $0.00 |
| Meyer Steven JDirector | Mar 5, 2018 | Grant | 4,000 | $0.00 |
| Lapalme PierreDirector | Mar 5, 2018 | Grant | 4,000 | $0.00 |
| Vishnoi RohitDirector | Mar 5, 2018 | Grant | 6,000 | $0.00 |
| Vishnoi RohitDirector | Mar 5, 2018 | Grant | 6,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Other material eventFeb 11, 2020
- Regulation FD disclosureFeb 10, 2020
- Entered a material agreementFeb 5, 2020
- Regulation FD disclosureJan 17, 2020
- Regulation FD disclosureJan 10, 2020
- Entered a material agreement · Regulation FD disclosureJan 6, 2020
- Regulation FD disclosure · Other material eventDec 26, 2019
- Entered a material agreement · Changed auditor · Regulation FD disclosureDec 3, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.